Legal Representation
Attorney
GLENN A GUNDERSEN
USPTO Deadlines
Application History
39 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 14, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Aug 14, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jan 13, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 11, 2023 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Jan 11, 2023 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Jan 11, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 14, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 12, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jul 12, 2022 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jul 12, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 13, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 11, 2022 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jan 11, 2022 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jan 11, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 14, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 12, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jul 12, 2021 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jul 12, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 12, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 3, 2020 | TMBN | T | TTAB RELEASE CASE TO TRADEMARKS | Loading... |
| Dec 3, 2020 | OP.T | T | OPPOSITION TERMINATED NO. 999999 | Loading... |
| Nov 2, 2020 | OP.D | T | OPPOSITION DISMISSED NO. 999999 | Loading... |
| Nov 14, 2019 | OP.I | T | OPPOSITION INSTITUTED NO. 999999 | Loading... |
| Nov 7, 2019 | OPPF | T | OPPOSITION PAPERS RECEIVED AT TTAB | Loading... |
| Oct 8, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 8, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 18, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 5, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Sep 3, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 24, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 23, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 23, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 26, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 26, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 26, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 25, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 13, 2018 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Dec 12, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 26, 2018 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
House mark for pharmaceutical and medical preparations for the treatment of oncology, autoimmune, immune-oncology and other related diseases; House mark for pharmaceutical and medical therapeutics for the treatment of oncology, autoimmune, immune-oncology and other related diseases; House mark for diagnostic reagents for the treatment of oncology, autoimmune, immune-oncology and other related diseases
Class 042
Research and development of therapeutic drugs for the treatment of oncology, autoimmune, immune-oncology and other related diseases; Research and development of therapeutic antibodies and pharmaceuticals, and research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; Development of pharmaceutical preparations and medicines; Drug development and discovery; Medical research for development of therapeutic modalities for treatment of diseases; Assays and reagents for use in scientific and biomedical research; Clinical studies; Preclinical and clinical development of therapeutic products
Additional Information
Design Mark
The mark consists of several geometric designs that form the basic elements of an animal face, to the right of the design appears the wording "KYMERA THERAPEUTICS" in capital stylized letters.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"